Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and other neurodegenerative diseases. The company's lead product candidate, AMX0035, is a combination therapy designed to reduce the death of motor neurons. Amylyx was founded in 2013 by Joshua Cohen, Justin Klee, and Justin Yang, and is headquartered in Cambridge, Massachusetts.